CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

– Formation of a Scientific Advisory Committee from world-renowned cancer institutions –

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle's clinical research experience. The corrected release follows:

AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology's new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Dr. Braendle brings more than twenty years of clinical research experience to AVEO Oncology, most recently serving as Chief Development Officer of Autolus Therapeutics Plc since July 2021, where he was responsible for all development functions and the conduct of a pivotal program in CD-19 directed genetically modified autologous T cell immunotherapy for adult acute lymphoblastic leukemia, and the respective filing to the U.S. Food & Drug Administration and European Medicines Agency.

“We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company. “Dr. Braendle’s significant experience will be instrumental in our efforts to develop and diversify our pipeline.”

Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice President, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology, where he was responsible for a full range of development functions and progressed several early-stage, first in human programs and late-stage programs. Prior to this, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic reference laboratory. Dr. Braendle also spent over a decade at Novartis AG, where he served as Senior Vice President and Global Head of Companion Diagnostics and led the company's precision medicine approach. Dr. Braendle received his medical degree at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology. Dr. Braendle is also an associate professor at the University of Ulm, Germany.
Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee ("Committee"). This esteemed group of experts in oncology research and clinical development were selected to advise and bring unique perspectives to AVEO and LG Chem's clinical strategy and business development initiatives. "We are excited and privileged to have the opportunity to work with this group of top oncology experts to help guide our drug development initiatives from discovery through commercialization. Notably, the Committee represents key areas of interest including gastrointestinal, genitourinary, ovarian, lung and head and neck cancers," said Mr. Bailey.

The Scientific Advisory Committee is comprised of several leading cancer experts, including:

**Al B. Benson III, MD, FACP, FACCC, FASCO**  
Professor of Medicine  
Associate Director from Cooperative Groups  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

**Scott Kopetz, MD, PhD**  
Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology  
Division of Cancer Medicine  
University of Texas MD Anderson Cancer Center

**D. Ross Camidge, MD, PhD**  
Professor of Medicine/Oncology  
Joyce Zeff Chair in Lung Cancer  
Director, Thoracic Oncology  
Faculty, Developmental Therapeutics Program  
University of Colorado Cancer Center, Aurora

**John L. Marshall, MD**  
Chief, Hematology and Oncology  
Professor of Medicine and Oncology  
Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers  
Georgetown Lombardi Comprehensive Cancer Center

**Edward Chu, MD, MMS**  
Director, Montefiore Einstein Cancer Center  
Albert Einstein College of Medicine

**Tony S.K. Mok, BBS, FASCO**  
Chairman, Department of Clinical Oncology  
LiShu Fan Professor of Clinical Oncology  
The Chinese University of Hong Kong

**Ezra Cohen, MD, FRCPSC, FASCO**  
Chief Medical Officer of Oncology  
Tempsus  
University of California- San Diego

**Paul G. Richardson, MD**  
Director, Clinical Research  
Jerome Lipper Multiple Myeloma Center  
Dana-Farber Cancer Institute

**Kevin J. Cullen, MD**  
Professor of Oncology  
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center  
University of Maryland School of Medicine

**Joseph Tabernero, MD, PhD**  
Head, Medical Oncology Department  
Director, Vall d’Hebron Institute of Oncology  
Professor of Medicine, UVic-UCC

**Enrique Grande, MD, PhD, Msc**  
Director, Medical Oncology Program and Clinical Research lead  
MD Anderson Cancer Center Madrid

**Jan Vermorken, MD, PhD**  
Emeritus Professor of Oncology  
Department of Medical Oncology  
Antwerp University Hospital

---

**About AVEO Pharmaceuticals, Inc.**  
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immunoncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. For more information, please visit www.aveooncology.com.

**About LG Chem, Ltd. and LG Chem Life Sciences**  
LG Chem, Ltd. (LG Chem) is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company
manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem Life Sciences develops, manufactures, and globally commercializes pharmaceutical products, with a focus on Oncology, Immunology, and Metabolic diseases. Our mission is to transform people’s lives through inspiring science and leading innovation. For more information, please visit www.lgchem.com.

Contacts Media:
John F. Kouten
JFK Communications, Inc.
jfkouten@jfkhealth.com
(908) 227-4714
Source: AVEO Pharmaceuticals, Inc.